Amedeo Smart

Free Medical Literature Service

 

Amedeo

Urinary Tract Infection
  Free Subscription

Articles published in
J Antimicrob Chemother
    September 2025
  1. ELADAWY M, Heslop N, Negus D, Thomas JC, et al
    Phenotype-genotype discordance in antimicrobial resistance profiles of Gram-negative uropathogens recovered from catheter-associated urinary tract infections in Egypt.
    J Antimicrob Chemother. 2025 Sep 23:dkaf352. doi: 10.1093.
    >> Share

    July 2025
  2. STURM PDJ, Schulin T
    Rapid susceptibility testing on urine for antimicrobial stewardship in general practice.
    J Antimicrob Chemother. 2025;80:1926-1932.
    >> Share

  3. KOONG J, Hall RM, Hamidian M
    Genomic characteristics of the multiresistant Acinetobacter baumannii global clone 1 reference strain A297/RUH875.
    J Antimicrob Chemother. 2025;80:1988-1992.
    >> Share

    June 2025
  4. HONDA T, Vazquez-Montes MDLA, Fanshawe TR, Stoesser N, et al
    The impact of inter-infection time on antimicrobial resistance profiles in women with multiple urinary tract infections over time.
    J Antimicrob Chemother. 2025 Jun 24:dkaf194. doi: 10.1093.
    >> Share

  5. HANDAL N, Kaspersen H, Mo SS, Cabanel N, et al
    A comparative study of the molecular characteristics of human uropathogenic Escherichia coli collected from two hospitals in Norway and France in 2019.
    J Antimicrob Chemother. 2025;80:1707-1715.
    >> Share

    February 2025
  6. HUNTER CJ, Marhoffer EA, Holleck JL, Ein Alshaeba S, et al
    Effect of empiric antibiotics against Pseudomonas aeruginosa on mortality in hospitalized patients: a systematic review and meta-analysis.
    J Antimicrob Chemother. 2025;80:322-333.
    >> Share

    December 2024
  7. ZOHAR I, Ben David D, Schwartz O, Pomerantz A, et al
    Amikacin treatment in patients with Enterobacterales bacteraemia: impact of MIC on mortality.
    J Antimicrob Chemother. 2024;79:3204-3209.
    >> Share

    November 2024
  8. LEROY AG, Lemenand O, Thibaut S, Coeffic T, et al
    Assessment of co-resistance to antibiotics recommended for acute pyelonephritis among Escherichia coli clinical strains from community- and nursing home-acquired urinary tract infections.
    J Antimicrob Chemother. 2024 Nov 29:dkae431. doi: 10.1093.
    >> Share

  9. ABBOTT IJ, Anderson CRB, van Gorp E, Wallis SC, et al
    Oral ciprofloxacin biofilm activity in a catheter-associated urinary tract infection model.
    J Antimicrob Chemother. 2024 Nov 29:dkae424. doi: 10.1093.
    >> Share

  10. HERNANDEZ-LOZANO I, Aranzana-Climent V, Cao S, Matias C, et al
    Model-informed drug development for antimicrobials: translational pharmacokinetic-pharmacodynamic modelling of apramycin to facilitate prediction of efficacious dose in complicated urinary tract infections.
    J Antimicrob Chemother. 2024 Nov 16:dkae409. doi: 10.1093.
    >> Share

    October 2024
  11. MASSIP C, Feletti L, Chagneau CV, Dumont Y, et al
    Evaluation of several routine methods for fosfomycin and mecillinam susceptibility testing of Enterobacterales urine isolates.
    J Antimicrob Chemother. 2024;79:2645-2652.
    >> Share

    September 2024
  12. DIZI ISIK A, Akkoc G, Ergenc Z, Yilmaz S, et al
    The use of fosfomycin in infections caused by multidrug-resistant pathogens, especially pneumonia in children: a five-year retrospective single-centre experience.
    J Antimicrob Chemother. 2024;79:2179-2185.
    >> Share

    August 2024
  13. MEIJS AP, Chaname-Pinedo LE, Deng H, Veldman KT, et al
    Association between antimicrobial usage in livestock and antimicrobial resistance in Escherichia coli isolates from human urinary tract infections in the Netherlands, 2009-2020.
    J Antimicrob Chemother. 2024 Aug 2:dkae268. doi: 10.1093.
    >> Share

    July 2024
  14. WIJNANT GJ, Ngougni Pokem P, Coessens M, Cottone E, et al
    Pharmacokinetics and pharmacological target attainment of standard temocillin dosing in non-critically ill patients with complicated urinary tract infections.
    J Antimicrob Chemother. 2024 Jul 10:dkae215. doi: 10.1093.
    >> Share

    May 2024
  15. TUINTE RAM, van Zanten MD, Takamura T, Schoffelen T, et al
    Follow-up of patients with urinary tract infections discharged from the emergency department: a mixed methods study.
    J Antimicrob Chemother. 2024 May 31:dkae169. doi: 10.1093.
    >> Share

  16. MENENDEZ ALVARADO LR, Margulis Landayan A, Williams KN, Frederick CM, et al
    Impact of removing ESBL status labelling from culture reports on the use of carbapenems for non-bacteraemic patients diagnosed with ESBL-positive urinary tract infections.
    J Antimicrob Chemother. 2024 May 8:dkae135. doi: 10.1093.
    >> Share

  17. RECH MA, Faine BA, Gross AE, Vakkalanka P, et al
    Empirical antimicrobial prescribing for pyelonephritis in patients discharged from 15 US Emergency Departments: an opportunity for improvement.
    J Antimicrob Chemother. 2024;79:1038-1044.
    >> Share

    March 2024
  18. HELTVEIT-OLSEN SR, Gopinathan U, Blix HS, Elstrom P, et al
    Effect of methenamine hippurate shortage on antibiotic prescribing for urinary tract infections in Norway-an interrupted time series analysis.
    J Antimicrob Chemother. 2024 Mar 28:dkae078. doi: 10.1093.
    >> Share

    February 2024
  19. BAYART J, Drouet J, Peycelon M, Mariani P, et al
    Temocillin for febrile urinary tract infections caused by ESBL-producing Enterobacteriaceae in children: a monocentric exposed/non-exposed study.
    J Antimicrob Chemother. 2024 Feb 27:dkae053. doi: 10.1093.
    >> Share

  20. PIAZZOLLA HRW, Modin F, Halkjaer SI, Petersen AM, et al
    The association between bacteriuria and adverse pregnancy outcomes: a systematic review and meta-analysis of observational studies.
    J Antimicrob Chemother. 2024;79:241-254.
    >> Share

    January 2024
  21. MONTELIN H, Camporeale A, Hallgren A, Angelin M, et al
    Treatment, outcomes and characterization of pathogens in urinary tract infections caused by ESBL-producing Enterobacterales: a prospective multicentre study.
    J Antimicrob Chemother. 2024 Jan 10:dkad402. doi: 10.1093.
    >> Share

  22. ARYEE A, Rockenschaub P, Robson J, Ahmed Z, et al
    Assessing the impact of discordant antibiotic treatment on adverse outcomes in community-onset UTI: a retrospective cohort study.
    J Antimicrob Chemother. 2024;79:134-142.
    >> Share

    December 2023
  23. HATTORI Y, Tahara S, Aso S, Makito K, et al
    Comparison of prophylactic antibiotics for endonasal transsphenoidal surgery using a national inpatient database in Japan.
    J Antimicrob Chemother. 2023;78:2909-2914.
    >> Share

    November 2023
  24. KASHOURIS E, Joseph A, Lewis T
    Nitrofurantoin: what is the evidence for current UK guidance?
    J Antimicrob Chemother. 2023;78:2605-2611.
    >> Share

  25. TORRES A, Wible M, Tawadrous M, Irani P, et al
    Efficacy and safety of ceftazidime/avibactam in patients with infections caused by beta-lactamase-producing Gram-negative pathogens: a pooled analysis from the Phase 3 clinical trial programme.
    J Antimicrob Chemother. 2023;78:2672-2682.
    >> Share

    September 2023
  26. NGUYEN HM, Flerchinger S, Smith JR, Felcher AH, et al
    Diagnostic and antibiotic stewardship lessons: an outpatient assessment of symptomatic reflex urinalysis ordering accuracy using an electronic best-practice alert.
    J Antimicrob Chemother. 2023;78:2283-2290.
    >> Share

    August 2023
  27. CARTER C, Hutchison A, Rudder S, Trotter E, et al
    Uropathogenic Escherichia coli population structure and antimicrobial susceptibility in Norfolk, UK.
    J Antimicrob Chemother. 2023;78:2028-2036.
    >> Share

    July 2023
  28. FANSHAWE TR, Judge RK, Mort S, Butler CC, et al
    Evidence-based appraisal of two guidelines for the diagnosis of suspected, uncomplicated urinary tract infections in primary care: a diagnostic accuracy validation study.
    J Antimicrob Chemother. 2023 Jul 4:dkad212. doi: 10.1093.
    >> Share

    June 2023
  29. SOJO-DORADO J, Lopez-Hernandez I, Hernandez-Torres A, Retamar-Gentil P, et al
    Effectiveness of fosfomycin trometamol as oral step-down therapy for bacteraemic urinary tract infections due to MDR Escherichia coli: a post hoc analysis of the FOREST randomized trial.
    J Antimicrob Chemother. 2023 Jun 1:dkad147. doi: 10.1093.
    >> Share

  30. MAHER JM, Huband MD, Blankers CG, Puttagunta S, et al
    In vitro activity of sulopenem and comparator agents against Enterobacterales and anaerobic clinical isolates collected during the SENTRY Antimicrobial Surveillance Program.
    J Antimicrob Chemother. 2023;78:1406-1414.
    >> Share

    May 2023
  31. PURCELL R, Yeoh D, Bowen A, Britton PN, et al
    A multicentre, retrospective audit of fosfomycin use for urinary tract infections in Australian children and adolescents.
    J Antimicrob Chemother. 2023 May 16:dkad131. doi: 10.1093.
    >> Share

    March 2023
  32. WATKINS RR, Thapaliya D, Lemonovich TL, Bonomo RA, et al
    Gepotidacin: a novel, oral, 'first-in-class' triazaacenaphthylene antibiotic for the treatment of uncomplicated urinary tract infections and urogenital gonorrhoea.
    J Antimicrob Chemother. 2023 Mar 8:dkad060. doi: 10.1093.
    >> Share

    February 2023
  33. VALLEE M, Harding C, Hall J, Aldridge PD, et al
    Exploring the in situ evolution of nitrofurantoin resistance in clinically derived uropathogenic Escherichia coli isolates.
    J Antimicrob Chemother. 2023;78:373-379.
    >> Share

  34. ABBOTT IJ, van Gorp E, Cottingham H, Macesic N, et al
    Oral ciprofloxacin activity against ceftriaxone-resistant Escherichia coli in an in vitro bladder infection model.
    J Antimicrob Chemother. 2023;78:397-410.
    >> Share

    January 2023
  35. CHEN L, Hua J, Hong SJ, Yuan CY, et al
    Comparison of the relative efficacy of beta-lactam/beta-lactamase inhibitors and carbapenems in the treatment of complicated urinary tract infections caused by ceftriaxone-non-susceptible Enterobacterales: a multicentre retrospective observational coh
    J Antimicrob Chemother. 2023 Jan 24:dkac448. doi: 10.1093.
    >> Share

    December 2022
  36. FRIMODT-MOLLER N, Simonsen GS, Larsen AR, Kahlmeter G, et al
    Pivmecillinam, the paradigm of an antibiotic with low resistance rates in Escherichia coli urine isolates despite high consumption.
    J Antimicrob Chemother. 2022;78:289-295.
    >> Share

    November 2022
  37. GUO S, Li X, Li Y, Tong H, et al
    Sitafloxacin pharmacokinetics/pharmacodynamics against multidrug-resistant bacteria in a dynamic urinary tract infection in vitro model.
    J Antimicrob Chemother. 2022 Nov 4. pii: 6795394. doi: 10.1093.
    >> Share

    September 2022
  38. WALKTY AJ, Karlowsky JA, Baxter MR, Lagace-Wiens PRS, et al
    In vitro activity of sulopenem against 1880 bacterial pathogens isolated from Canadian patients with urinary tract infections (CANWARD, 2014-21).
    J Antimicrob Chemother. 2022 Sep 30. pii: 6731707. doi: 10.1093.
    >> Share

    July 2022
  39. EMERAUD C, Godmer A, Girlich D, Vanparis O, et al
    Activity of mecillinam against carbapenem-resistant Enterobacterales.
    J Antimicrob Chemother. 2022 Jul 11. pii: 6639593. doi: 10.1093.
    >> Share

    April 2022
  40. ABBOTT IJ, van Gorp E, Wyres KL, Wallis SC, et al
    Oral fosfomycin activity against Klebsiella pneumoniae in a dynamic bladder infection in vitro model.
    J Antimicrob Chemother. 2022;77:1324-1333.
    >> Share

  41. FUCHS F, Becerra-Aparicio F, Xanthopoulou K, Seifert H, et al
    In vitro activity of nitroxoline against carbapenem-resistant Acinetobacter baumannii isolated from the urinary tract.
    J Antimicrob Chemother. 2022 Apr 12. pii: 6566767. doi: 10.1093.
    >> Share

    March 2022
  42. NEVILLE LF, Shalit I, Warn PA, Rendell JT, et al
    Vancomycin-arginine (STM-001) abrogates ESBL carrier and carbapenem-resistant Escherichia coli burden in a murine complicated urinary tract infection model.
    J Antimicrob Chemother. 2022 Mar 1. pii: 6539950. doi: 10.1093.
    >> Share


Free Medical Abstracts
Privacy Policy
Sponsors
Share

© Amedeo 1997-2016